UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Evolution of platelets in chronic hepatitis C infected patients and advanced liver fibrosis after direct-acting antiviral treatment

Journal of hepatology, 2017, Vol.66 (1), p.S311-S312

2017

Link zum Volltext

Verfügbarkeit prüfen

Changes in the lipid profile in hepatitis C virus infected patients treated with direct-acting antivirals

Journal of hepatology, 2017, Vol.66 (1), p.S729-S729

2017

Link zum Volltext

Verfügbarkeit prüfen

The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients

Journal of hepatology, 2017, Vol.66 (1), p.S156-S156

2017

Link zum Volltext

Verfügbarkeit prüfen

Protective effect of quercetin treatment on HFD-induced intestinal dysbiosis and barrier dysfunction in an in vivo model of non-alcoholic fatty liver disease

Journal of hepatology, 2017, Vol.66 (1), p.S169-S169

2017

Link zum Volltext

Verfügbarkeit prüfen

Adherence to SmPC recommendations in real-world practice in the treatment of monoinfected patients with chronic genotype 1 or 4 HCV infection with direct-acting antivirals

Journal of hepatology, 2017, Vol.66 (1), p.S522-S523

2017

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice

Journal of hepatology, 2017, Vol.66 (1), p.S523-S524

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Interferon-Free Therapy in Cirrhotic and Non-Cirrhotic Chronic Hepatitis C Patients in Clinical Practice

Journal of hepatology, 2016, Vol.64 (2), p.S765-S765

2016

Link zum Volltext

Verfügbarkeit prüfen

Simeprevir and Sofosbuvir with or without Ribavirin in Genotype 1 Chronic Hepatitis C Patients: Efficacy and Safety in Real Life

Journal of hepatology, 2016, Vol.64 (2), p.S765-S766

2016

Link zum Volltext

Verfügbarkeit prüfen

High Efficacy of Interferon-Free Treatments in Real-World Patients with Chronic Hepatitis C a Multicentric Study

Journal of hepatology, 2016, Vol.64 (2), p.S764-S765

2016

Link zum Volltext

Verfügbarkeit prüfen

P0720 : Improvement of advanced liver fibrosis and regression of liver cirrhosis in patients with hepatitis C genotype 1 after HCV protease inhibitor-based triple therapy

Journal of hepatology, 2015-04, Vol.62, p.S594-S594

2015

Link zum Volltext

Verfügbarkeit prüfen

P1041 TENOFOVIR MONOTHERAPY VERSUS LAMIVUDINE PLUS ADEFOVIR IN LAMIVUDINE-FAILURE PATIENTS RESCUED WITH LAMIVUDINE PLUS ADEFOVIR COMBINATION: INTERIM ANALYSIS OF THE TENOSIMP-B CLINICAL TRIAL

Journal of hepatology, 2014-04, Vol.60 (1), p.S422-S422

2014

Link zum Volltext

Verfügbarkeit prüfen

P1178 TELAPREVIR-BASED TRIPLE THERAPY IN PATIENTS WITH MODERATE FIBROSIS. SPANISH MULTICENTRE STUDY IN CLINICAL PRACTICE

Journal of hepatology, 2014-04, Vol.60 (1), p.S478-S478

2014

Link zum Volltext

Verfügbarkeit prüfen

868 LIVER X RECEPTOR a-MEDIATED LIPOGENESIS INDUCED BY HEPATITIS C VIRUS NS5A AND CORE PROTEINS REGULATES VIRAL REPLICATION IN AN IN VITRO MODEL

Journal of hepatology, 2012-04, Vol.56, p.S338-S338

2012

Link zum Volltext

Verfügbarkeit prüfen

P1198 EFFECTIVENESS OF TRIPLE THERAPY IN CLINICAL PRACTICE FOR TREATMENT-NAIVE HCV PATIENTS WITH ADVANCED HEPATIC FIBROSIS. VIROLOGIC RESPONSE DATA AT 12 WEEKS POST-TREATMENT (SVR-12W)

Journal of hepatology, 2014-04, Vol.60 (1), p.S486-S487

2014

Link zum Volltext

Verfügbarkeit prüfen

Análisis descriptivo de los hallazgos endoscópicos en pacientes con antecedentes familiares de cáncer colorrectal

Revista de gastroenterología de México, 2015-07, Vol.80 (3), p.192-197

2015

Link zum Volltext

Verfügbarkeit prüfen

1109 HIGH VS STANDARD DOSE OF RIBAVIRIN PLUS PEGINTERFERON-ALFA-2A IN CHRONIC HEPATITIS C, GENOTYPE 3 AND HIGH VIRAL LOAD. FINAL RESULTS OF THE DARGEN-3 STUDY

Journal of hepatology, 2012-04, Vol.56, p.S437-S437

2012

Link zum Volltext

Verfügbarkeit prüfen

804 EFFECT OF HCV NS5A AND CORE PROTEINS AND VIRAL REPLICATION ON LXRa-MEDIATED LIPOGENIC GENES INDUCTION IN AN IN VITRO MODEL

Journal of hepatology, 2011-03, Vol.54, p.S323-S323

2011

Link zum Volltext

Verfügbarkeit prüfen

1097 CARDIOTROPHIN-1 DEFENDS AGAINST VIRAL-INDUCED LETHAL ACUTE LIVER FAILURE (ALF) OF RABBITS BY ATTENUATING LIVER INFLAMMATION AND INDUCING CYTOPROTECTIVE GROWTH FACTORS

Journal of hepatology, 2011-03, Vol.54, p.S434-S434

2011

Link zum Volltext

Verfügbarkeit prüfen

171 MAP KINASE-DEPENDENT PATHWAYS ARE ACTIVATED DURING PROGRAMMED CELL DEATH IN A VIRAL MODEL OF FULMINANT HEPATIC FAILURE

Journal of hepatology, 2008, Vol.48, p.S73-S73

2008

Link zum Volltext

Verfügbarkeit prüfen

1001 INTERIM ANALYSIS FROM TRIC-1 A STUDY OF METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HEPATITIS C WITH INSULIN RESISTANCE

Journal of hepatology, 2008, Vol.48, p.S375-S375

2008

Link zum Volltext

Verfügbarkeit prüfen

Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy

The American journal of gastroenterology, 2001, Vol.96 (8), p.2456-2461

2001

Link zum Volltext

Verfügbarkeit prüfen

Endoscopic ultrasonography in the diagnosis of aortoesophageal fistula

The American journal of gastroenterology, 2000, Vol.95 (5), p.1374-1375

2000

Link zum Volltext

Verfügbarkeit prüfen

Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]

Gastroenterología y hepatología, 2018-08, Vol.41 (7), p.475-476

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(41)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evolution of platelets in chronic hepatitis C infected patients and advanced liver fibrosis after direct-acting antiviral treatment

Changes in the lipid profile in hepatitis C virus infected patients treated with direct-acting antivirals

The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients

Protective effect of quercetin treatment on HFD-induced intestinal dysbiosis and barrier dysfunction in an in vivo model of non-alcoholic fatty liver disease

Adherence to SmPC recommendations in real-world practice in the treatment of monoinfected patients with chronic genotype 1 or 4 HCV infection with direct-acting antivirals

Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice

Efficacy of Interferon-Free Therapy in Cirrhotic and Non-Cirrhotic Chronic Hepatitis C Patients in Clinical Practice

Simeprevir and Sofosbuvir with or without Ribavirin in Genotype 1 Chronic Hepatitis C Patients: Efficacy and Safety in Real Life

High Efficacy of Interferon-Free Treatments in Real-World Patients with Chronic Hepatitis C a Multicentric Study

P0720 : Improvement of advanced liver fibrosis and regression of liver cirrhosis in patients with hepatitis C genotype 1 after HCV protease inhibitor-based triple therapy

Effectiveness and Safety of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir Patients with Genotype 1 Chronic Hepatitis C Virus Infection: Results from the Spanish Real World Cohort

Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C Cohort

P1041 TENOFOVIR MONOTHERAPY VERSUS LAMIVUDINE PLUS ADEFOVIR IN LAMIVUDINE-FAILURE PATIENTS RESCUED WITH LAMIVUDINE PLUS ADEFOVIR COMBINATION: INTERIM ANALYSIS OF THE TENOSIMP-B CLINICAL TRIAL

P1178 TELAPREVIR-BASED TRIPLE THERAPY IN PATIENTS WITH MODERATE FIBROSIS. SPANISH MULTICENTRE STUDY IN CLINICAL PRACTICE

868 LIVER X RECEPTOR a-MEDIATED LIPOGENESIS INDUCED BY HEPATITIS C VIRUS NS5A AND CORE PROTEINS REGULATES VIRAL REPLICATION IN AN IN VITRO MODEL

P1198 EFFECTIVENESS OF TRIPLE THERAPY IN CLINICAL PRACTICE FOR TREATMENT-NAIVE HCV PATIENTS WITH ADVANCED HEPATIC FIBROSIS. VIROLOGIC RESPONSE DATA AT 12 WEEKS POST-TREATMENT (SVR-12W)

Análisis descriptivo de los hallazgos endoscópicos en pacientes con antecedentes familiares de cáncer colorrectal

1109 HIGH VS STANDARD DOSE OF RIBAVIRIN PLUS PEGINTERFERON-ALFA-2A IN CHRONIC HEPATITIS C, GENOTYPE 3 AND HIGH VIRAL LOAD. FINAL RESULTS OF THE DARGEN-3 STUDY

804 EFFECT OF HCV NS5A AND CORE PROTEINS AND VIRAL REPLICATION ON LXRa-MEDIATED LIPOGENIC GENES INDUCTION IN AN IN VITRO MODEL

1097 CARDIOTROPHIN-1 DEFENDS AGAINST VIRAL-INDUCED LETHAL ACUTE LIVER FAILURE (ALF) OF RABBITS BY ATTENUATING LIVER INFLAMMATION AND INDUCING CYTOPROTECTIVE GROWTH FACTORS

171 MAP KINASE-DEPENDENT PATHWAYS ARE ACTIVATED DURING PROGRAMMED CELL DEATH IN A VIRAL MODEL OF FULMINANT HEPATIC FAILURE

1001 INTERIM ANALYSIS FROM TRIC-1 A STUDY OF METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HEPATITIS C WITH INSULIN RESISTANCE

Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy

Endoscopic ultrasonography in the diagnosis of aortoesophageal fistula

Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]

Aktive Filter

Suchergebnisse filtern